Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05204927
Phase 3 Trial of 177Lu-PSMA I&T versus Hormone Therapy in Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
Overview
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Sponsor
CuriumPhase
Phase 3
Contacts
Darcy Denner, Ph.D. (Clinical Trial Director)
darcy.denner@curiumpharma.com
ClinicalTrials.gov
NCT05204927Drug / Compound
Isotope(s):
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
Educational Video
Eligibility
Inclusion
- Males, 18 years or older
- Positive PSMA PET scan
- Proven metastatic castration-resistant prostate cancer
Exclusion
- Previous treatment with chemotherapy in the castration-resistant setting
- Previous treatment with more than one ARAT
- Previous treatment with other radioligand therapy
Patient Education
Publications
Publications not yet provided.
Locations
Loading…
Share your feedback
Help us improve your experience